Genus PLC (GB:GNS)
LSE:GNS
Top Page
Genus plc
(LSE:GNS)
Select Model
Select Model
Rating:69Neutral
Price Target:
3,154.00 p
▲(29.79% Upside)
Action:ReiteratedDate:12/07/25
Genus plc's overall stock score is driven by strong corporate events and solid financial performance. However, technical indicators suggest caution due to potential overbought conditions, and the high P/E ratio indicates possible overvaluation.
Positive Factors
Market leadership in animal genetics
Leading position in animal genetics provides durable competitive advantages: proprietary breeding programs, scale in semen/embryo supply, deep industry relationships and technical expertise. These create high barriers to entry and sustained demand from commercial livestock producers worldwide.
Negative Factors
Volatile free cash flow
Volatility in free cash flow creates uncertainty for capital allocation: it can constrain steady R&D, acquisitions or shareholder returns and complicate debt repayment planning. Persistent FCF swings suggest sensitivity to capex timing or working-capital cycles.
Read all positive and negative factors
Positive Factors
Negative Factors
Market leadership in animal genetics
Leading position in animal genetics provides durable competitive advantages: proprietary breeding programs, scale in semen/embryo supply, deep industry relationships and technical expertise. These create high barriers to entry and sustained demand from commercial livestock producers worldwide.
Read all positive factors
Genus plc (GNS) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£1.61B
Dividend Yield1.25%
Average Volume (3M)171.79K
Price to Earnings (P/E)14.4
Beta (1Y)1.83
Revenue Growth0.60%
EPS Growth143.39%
CountryUK
Employees3,500
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.60
Shares Outstanding66,538,290
10 Day Avg. Volume120,789
30 Day Avg. Volume171,792
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)2.83
Price to Sales (P/S)2.00
P/FCF Ratio27.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£3,137.50Price Target Upside29.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)1.07
Revenue Forecast (FY)£678.55M
Genus plc Business Overview & Revenue Model
Company Description
Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research ...
How the Company Makes Money
Genus generates revenue through several key streams. Primarily, the company earns money from the sale of genetic materials, such as semen and embryos, to livestock producers. These products are essential for breeding programs aimed at improving an...
Genus plc Earnings Call Summary
Earnings Call Date:Feb 27, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Sep 03, 2026
Earnings Call Sentiment Positive
The earnings call reflects a strong financial performance and strategic progress, particularly with PIC's growth and the VAP initiatives. However, ABS faces challenges in China and Brazil, and currency headwinds are impacting profitability. R&D spend has decreased, but the company remains committed to innovation. Overall, the positive aspects outweigh the negatives.Positive Updates
Strong Financial Performance in H1 FY25
Adjusted operating profit grew 19% to GBP 45.2 million, and adjusted profit before tax grew 21% to GBP 35.4 million. This was a record first-half performance.
Negative Updates
Challenges in ABS China and Brazil
ABS China continues to be extremely challenged, with a 9% contraction in Chinese dairy production. ABS China profits were down GBP 1.6 million year-on-year. Brazil beef demand remains weak.
Read all updates
Q2-2025 Updates
Positive
Negative
Strong Financial Performance in H1 FY25
Adjusted operating profit grew 19% to GBP 45.2 million, and adjusted profit before tax grew 21% to GBP 35.4 million. This was a record first-half performance.
Read all positive updates
Company Guidance
In the call, Genus provided comprehensive guidance highlighting several key metrics. PIC, excluding China, achieved a notable 13% increase in operating profit for the first half of the fiscal year 2025. Despite challenges in China, Genus signed seven new royalty customers, establishing contracts with three of the top five producers in the largest porcine market globally. The company's Value Acceleration Program (VAP) is on track to deliver a GBP 21 million annual run rate benefit by the end of the fiscal year, with notable improvements in cash flow due to better inventory management. Adjusted operating profit saw a 19% growth, reaching GBP 45.2 million, and adjusted profit before tax increased by 21% to GBP 35.4 million. The interim dividend was maintained at 10.3p per share. Additionally, the company expects FDA approval for its PRRS Resistant Pig (PRP) in calendar year 2025, with ongoing regulatory engagements in other international markets showing promise. Despite foreign exchange headwinds, Genus reaffirmed its fiscal year 2025 profit before tax (PBT) guidance, anticipating significant growth in PBT in actual currency.Genus plc Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
70
Positive
Cash Flow
65
Positive
| Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 672.00M | 672.80M | 668.80M | 689.70M | 593.40M | 574.30M |
| Gross Profit | 672.50M | 672.80M | 178.70M | 239.30M | 226.00M | 232.20M |
| EBITDA | 111.10M | 93.70M | 73.70M | 87.50M | 79.80M | 82.30M |
| Net Income | 47.50M | 19.30M | 7.90M | 33.30M | 40.90M | 47.30M |
Balance Sheet | ||||||
| Total Assets | 921.30M | 899.00M | 1.03B | 1.01B | 1.02B | 851.00M |
| Cash, Cash Equivalents and Short-Term Investments | 43.40M | 48.00M | 42.50M | 36.30M | 38.80M | 46.00M |
| Total Debt | 277.70M | 265.90M | 291.20M | 232.10M | 223.80M | 151.60M |
| Total Liabilities | 417.40M | 423.00M | 485.00M | 440.30M | 445.80M | 354.40M |
| Stockholders Equity | 504.00M | 475.60M | 548.20M | 569.40M | 578.50M | 498.10M |
Cash Flow | ||||||
| Free Cash Flow | 57.20M | 48.60M | 5.10M | 15.20M | -7.80M | 38.80M |
| Operating Cash Flow | 70.70M | 67.20M | 29.80M | 50.40M | 34.30M | 67.50M |
| Investing Cash Flow | -18.50M | -13.80M | -19.30M | -30.90M | -67.20M | -46.70M |
| Financing Cash Flow | -48.90M | -46.60M | -2.80M | -18.20M | 21.90M | -14.20M |
Genus plc Technical Analysis
Negative
2430.00
Price Trends
2861.79
Negative
2690.74
Negative
2546.30
Negative
Market Momentum
-103.43
Positive
31.18
Neutral
25.13
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:GNS, the sentiment is Negative. The current price of 2430 is below the 20-day moving average (MA) of 2660.93, below the 50-day MA of 2861.79, and below the 200-day MA of 2546.30, indicating a bearish trend. The MACD of -103.43 indicates Positive momentum. The RSI at 31.18 is Neutral, neither overbought nor oversold. The STOCH value of 25.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:GNS.
Genus plc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | £71.84M | 18.93 | 66.44% | 8.33% | -3.61% | -6.35% | |
69 Neutral | £1.61B | 14.39 | 9.70% | 1.25% | 0.60% | 143.39% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | £1.10B | -8.50 | -29.43% | ― | 22.03% | 20.01% | |
44 Neutral | £15.94M | -9.67 | -210.32% | ― | -11.43% | 23.40% | |
41 Neutral | £78.97M | -4.89 | -63.53% | ― | 198.49% | -26.66% | |
40 Underperform | £8.80M | -0.25 | -316.67% | ― | 72.17% | 79.03% |
* Healthcare Sector Average
GB:GNS
Genus plc
2,430.00
570.19
30.66%
GB:BVXP
Bioventix
1,375.00
-1,200.05
-46.60%
GB:OBD
Oxford BioDynamics
0.21
-0.28
-57.29%
GB:FAB
Fusion Antibodies Plc
12.75
6.25
96.15%
GB:4BB
4basebio UK Societas
510.00
-615.00
-54.67%
GB:ONT
Oxford Nanopore Technologies PLC
113.60
8.60
8.19%
Genus plc Corporate Events
Regulatory Filings and Compliance
Genus Director Celia Baxter Increases Stake with Share Purchase
Positive
Feb 27, 2026
Genus plc has disclosed that non-executive director Celia Baxter bought 1,728 ordinary shares in the company on 27 February 2026 on the London Stock Exchange at an average price of £28.92865 per share. The purchase, classified as a director d...
Business Operations and StrategyDividendsFinancial Disclosures
Genus Delivers Record Half-Year Profits and Advances China JV and Gene-Edited Pig Strategy
Positive
Feb 26, 2026
Genus reported record first-half profits for the six months to 31 December 2025, as adjusted operating profit jumped on strong performance at its porcine unit PIC, a milestone payment from Chinese partner Beijing Capital Agribusiness and ongoing c...
Regulatory Filings and Compliance
Genus Reports Stable Balances in Employee Share Schemes in Latest Block Listing Return
Neutral
Feb 2, 2026
Genus plc has released its latest six-monthly block listing return covering the period from 1 August 2025 to 31 January 2026, detailing movements in shares available under its employee and executive share schemes. The company reported that the 200...
Regulatory Filings and Compliance
Genus Confirms Total Voting Rights and Share Capital Structure
Neutral
Feb 2, 2026
Genus plc has confirmed that as of 31 January 2026 its issued share capital comprises 66,538,294 ordinary shares of 10 pence each, all carrying identical voting rights and with no shares held in treasury. This clarification of the company’s ...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Genus Secures $160m from Chinese Porcine Joint Venture and Reshapes PIC China Reporting
Positive
Feb 2, 2026
Genus plc has completed the formation of its Chinese porcine joint venture with Beijing Capital Agribusiness, a move it sees as the optimal platform to accelerate the growth of its PIC China business. The deal will bring Genus a gross cash payment...
Business Operations and StrategyFinancial DisclosuresM&A Transactions
Genus Completes Chinese Porcine Joint Venture, Unlocking $160m Cash Inflow
Positive
Feb 2, 2026
Genus plc, a global leader in animal genetics focused on dairy, beef and pork sectors, operates through its ABS and PIC brands to deliver advanced breeding products and services worldwide from its headquarters in Basingstoke. The company has compl...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Genus Wins Canadian Approval for Gene-Edited PRRS-Resistant Pig
Positive
Jan 23, 2026
Genus plc has secured regulatory approval in Canada for the use of its gene-edited PRRS Resistant Pig (PRP), marking a key milestone toward commercialising the technology in North America after years of collaboration with Canadian authorities. The...
Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
Genus Lifts Profit Outlook as China Porcine JV Wins Regulatory Approval
Positive
Jan 16, 2026
Genus reported a stronger-than-expected performance for the first half of its 2026 financial year, with adjusted profit before tax (excluding a milestone payment) anticipated at about £50m, ahead of internal expectations, and around £55....
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.